Fig. 1

NK cell frequencies and immunophenotypes after BNT162b2 mRNA vaccine administration. A Study design, experimental and analytical workflow on PBMC samples from healthy individuals and select patient groups with immunodeficiency disorders receiving two doses of the BNT162b2 mRNA vaccine according to label. B Gating strategy to identify natural killer (NK) cells and their subsets by flow cytometry. C NK cell absolute numbers based on the basal absolute lymphocyte count at Days 0, 21 and 35 in healthy study subjects (left panel) and immunocompromised patients (right panels). D Frequency of total NK cells based on the lymphocyte gate obtained by flow cytometry analysis at Days 0, 10, 21 and 35 in the healthy study subjects (left panel) and immunocompromised patients (right panels). E Frequency of NK cell subsets in healthy study subjects and immunocompromised patients. Healthy individuals (Day 0 n = 37, Day 10 n = 38, Day 21 n = 36, Day 35 n = 37), PLWH (Day 0 n = 48, Day 10 n = 46, Day 21 n = 44, Day 35 n = 44), PID (Day 0 n = 12, Day 10 n = 16, Day 21 n = 14, Day 35 n = 12), SOT (Day 0 n = 34, Day 10 n = 33, Day 21 n = 33, Day 35 n = 30). Statistical analysis for C, D and E was performed using a Kruskal–Wallis test followed by a Dunn´s multiple comparisons test. No statistical significance difference was observed within each respective group (i.e., when comparing days 0, 10, 21 and 35)